Recent Price Movement and Market Context
On 23 December 2025, Brooks Laboratories’ stock touched an intraday low of Rs.92.1, representing a fall of 2.33% on the day and underperforming its sector by 1.31%. This marks the fifth consecutive day of declines, with the stock registering a cumulative return of -5.94% over this period. The current price level is substantially below the stock’s 52-week high of Rs.202.8, indicating a considerable retracement over the past year.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish momentum. This contrasts with the broader market, where the Sensex, despite a slight dip of 0.01% to 85,557.41 points, remains close to its 52-week high of 86,159.02 and is supported by bullish moving averages.
Long-Term Performance and Comparative Analysis
Over the last twelve months, Brooks Laboratories has recorded a negative return of 45.08%, a stark contrast to the Sensex’s positive performance of 8.89% during the same period. The stock has also underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months, highlighting challenges in maintaining competitive market positioning.
Such underperformance is notable within the Pharmaceuticals & Biotechnology sector, which has generally exhibited resilience. The divergence suggests company-specific factors influencing investor sentiment and valuation.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Financial Metrics Reflecting Current Concerns
Brooks Laboratories’ long-term financial indicators reveal areas of concern. The company’s average Return on Equity (ROE) stands at 2.42%, which is considered weak relative to industry standards. Net sales have grown at an annual rate of 4.36% over the past five years, indicating modest expansion but falling short of robust growth expectations.
Debt servicing capacity is another area of note, with the average EBIT to interest ratio recorded at -3.69, suggesting challenges in covering interest expenses from operating earnings. This metric points to financial strain that may be influencing market perceptions.
Recent Quarterly and Half-Yearly Results
Despite the subdued stock performance, Brooks Laboratories has reported positive results in recent quarters. The company declared favourable outcomes for four consecutive quarters, with net sales for the latest six months reaching Rs.48.96 crores, reflecting a growth rate of 26.45%. Profit before tax excluding other income for the latest quarter stood at Rs.7.59 crores, showing a substantial increase of 2563.2% compared to the previous four-quarter average.
Operating cash flow for the year reached Rs.2.63 crores, the highest recorded, indicating improved cash generation capabilities. The company’s ROE for the latest period is 12.1, accompanied by a price-to-book value of 2.4, which suggests a fair valuation relative to its book value.
Valuation and Shareholding Structure
Brooks Laboratories is trading at a discount compared to its peers’ average historical valuations, which may reflect market caution given the company’s recent performance trends. The majority shareholding remains with promoters, indicating stable ownership control.
Over the past year, while the stock price has declined by 45.08%, the company’s profits have risen by 170.3%, resulting in a price/earnings to growth (PEG) ratio of 0.1. This disparity between profit growth and share price movement highlights a complex valuation scenario.
Brooks Laboratories or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector, to which Brooks Laboratories belongs, has generally maintained steady performance within the broader market. On the day of the stock’s new low, the Sensex opened positively but retreated to close marginally lower, while small-cap stocks led gains with the BSE Small Cap index rising by 0.44%.
Brooks Laboratories’ underperformance relative to both its sector and the broader market indices underscores company-specific factors influencing its share price trajectory.
Summary of Key Price and Performance Indicators
To summarise, Brooks Laboratories’ stock has reached Rs.92.1, its lowest level in 52 weeks, after a series of declines over five trading sessions. The stock’s position below all major moving averages and its negative returns over the past year contrast with the broader market’s relative strength. Financial metrics reveal modest sales growth, limited return on equity, and challenges in interest coverage, while recent quarterly results show some improvement in profitability and cash flow generation.
These factors collectively contribute to the current market valuation and price movement of Brooks Laboratories shares.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →
